In early research, subcutaneous nemolizumab significantly reduced pruritus in moderate-to-severe atopic dermatitis adult patients.
Biologic Treatments for Moderate to Severe Atopic Dermatitis
Long-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.
A new research center makes a database of five million human pathology specimens and 22,000 living consented patients, all searchable by diagnoses, as well as cutting edge human analytic techniques available to anyone interested in carrying out translational skin disease research on human cells and tissues.
New data suggests positive safety and efficacy profile. Further studies need to assess long-term use.
Microbial colonization in the development of inflammatory conditions and immune-mediated conditions is a hot research topic, and new dermatologic therapies can potentially result from greater understanding of the role of microbial communities on the skin and in the gut.
Part of the management of contact dermatitis is identifying the offending agent through patch testing and eliminating contact with the offending agent.
UK-based Ziarco Pharma Ltd. recently announced positive phase 2a results for ZPL-389, a once daily oral histamine H4 receptor antagonist, for the treatment of moderate to severe atopic dermatitis.
The systemic therapy dupilumab met primary endpoints in two phase 3 studies on adults with in inadequately controlled moderate-to-severe atopic dermatitis.
Pfizer and Anacor Pharmaceuticals announced in May that the pharmaceutical companies merged with Pfizer acquiring Anacor for about $5.2 billion. Dermatologists say merger is a good move for patients.
Good for more than a morning meal, oatmeal soothes angry skin, relieves itching, and even has an antimicrobial effect.